Anzeige
Meldung des Tages: Breaking News: TeaRx™ erobert Großbritannien im Sturm?!

Molecular Partners Aktie News

Aktie
WKN:  A12DEH ISIN:  CH0256379097 US-Symbol:  MLLCF Branche:  Biotechnologie Land:  Schweiz
3,70 CHF
-0,24 CHF
-6,09%
4,0482 € 20.02.26
Depot/Watchlist
Marktkapitalisierung *
135,87 Mio. €
Streubesitz
47,81%
KGV
-3,02
Index-Zuordnung
-

Molecular Partners News

02.02.26 - GlobeNewswire
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight ...
11.01.26 - GlobeNewswire
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
Phase 1/2a study with lead Radio-​DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026 Full imaging and dosimetry data from MP0712 ...
18.12.25 - GlobeNewswire
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-​stage biotech ...
11.12.25 - GlobeNewswire
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant ...
07.12.25 - GlobeNewswire
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimens Accelerated step-up dosing and higher dosing frequency is feasible and results in ...
12.11.25 - GlobeNewswire
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-...
03.11.25 - GlobeNewswire
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR  Molecular Partners AG (SIX: MOLN; ...
03.11.25 - GlobeNewswire
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
Poster presentation outlines potential of CD3 Switch-​DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell ...
30.10.25 - GlobeNewswire
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
IND application filed for MP0712, the Company’s lead Radio-​DARPin candidate targeting DLL3 and co-​developed with Orano Med, with Phase 1 initiation expected before year end ...
25.08.25 - GlobeNewswire
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under ...
21.08.25 - GlobeNewswire
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-​SCHLIEREN, Switzerland ...
22.06.25 - GlobeNewswire
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
MP0726, a Radio-​DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with ...
11.06.25 - GlobeNewswire
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 months Acceptable safety profile ...
10.06.25 - GlobeNewswire
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025 Cash reach now anticipated to extend into 2028 ZURICH-​SCHLIEREN, Switzerland and CONCORD, ...
19.05.25 - GlobeNewswire
Molecular Partners to Present at Upcoming Investor Conferences
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-​stage biotech ...
15.05.25 - GlobeNewswire
Molecular Partners Reports Financial Results and Highlights from Q1 2025
Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027 IND filing ...
25.04.25 - GlobeNewswire
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
Positive IND-​enabling data on MP0712 targeting DLL3, the most advanced Radio-​DARPin program in co-​development with Orano Med, entering clinical development in 2025 First ...
16.04.25 - GlobeNewswire
Molecular Partners Announces all Board Proposals Approved at Annual General Meeting
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-​stage biotech ...
25.03.25 - GlobeNewswire
Molecular Partners to hold three poster presentations at AACR 2025
Update on IND-​enabling data for MP0712, a Radio-​DARPin targeting DLL3 and labeled with 212 Pb, co-​developed with Orano Med; entering FIH studies in 2025 for the treatment of ...
25.03.25 - GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2025
ZURICH-​SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-​stage biotech ...

Newssuche

Videos

newspaper
18.02.26 -2,76%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Breaking News
DiagnosTear Technologies Inc
0,268 €
+5,51%
DiagnosTear Technologies Inc Chart
TeaRx™ erobert Großbritannien im Sturm?!
Mehr zur Aktie »